The journey to legalizing CBD in the United States has been complex, marked by evolving perceptions and regulatory frameworks. Initially, all forms of cannabis, including hemp, were classified as Schedule I substances under the Controlled Substances Act of 1970, making them illegal at the federal level. This classification did not differentiate between hemp and marijuana, despite their significant differences in THC content.
Early Developments and Medical Use
In the 1990s and early 2000s, increasing awareness of the potential therapeutic benefits of cannabis, including CBD, began to shift public opinion. States like California and Colorado pioneered medical marijuana legalization, allowing patients with certain conditions to use cannabis-derived products legally.
The 2014 Farm Bill
A significant milestone came with the Agricultural Act of 2014, commonly known as the 2014 Farm Bill. This legislation allowed for state-sanctioned pilot programs to study and grow industrial hemp, defined as cannabis with less than 0.3% THC. This was a crucial step in distinguishing hemp from marijuana and recognizing its potential for non-psychoactive uses.
The 2018 Farm Bill
The most transformative change occurred with the passage of the Agricultural Improvement Act of 2018, or the 2018 Farm Bill. This bill federally legalized the cultivation, production, and commercial distribution of hemp and hemp-derived CBD products, including CBD, as long as they contained no more than 0.3% THC. This legislation removed hemp from the list of controlled substances, effectively legalizing CBD derived from hemp.
FDA Involvement and Epidiolex Approval
In parallel with these legislative changes, the U.S. Food and Drug Administration (FDA) began to take a more active role in regulating CBD. In 2018, the FDA approved Epidiolex, a CBD-based medication for treating two rare forms of epilepsy, marking the first time a cannabis-derived product received FDA approval. This approval underscored the therapeutic potential of CBD and set a precedent for future medical applications.
The History of Legalizing CBD in the UK
The UK has also seen a gradual shift in its approach to CBD, with significant changes in public perception and regulatory frameworks over the past decade.
Early Restrictions
Initially, like many other countries, the UK had strict laws against all forms of cannabis, including hemp. The Misuse of Drugs Act 1971 classified cannabis as a Class B drug, making its cultivation, sale, and use illegal.
Emergence of CBD Products
In the early 2010s, CBD began to gain attention for its potential health benefits, and products containing CBD started to appear in the UK market. However, these products operated in a legal gray area, with no clear regulations governing their sale and distribution.
MHRA Announcement in 2016
A significant development occurred in 2016 when the Medicines and Healthcare products Regulatory Agency (MHRA) announced that CBD products intended for medical use needed to be licensed as medicines. This announcement marked the first official recognition of CBD’s therapeutic potential and set the stage for more formal regulation.
Legalization and Regulation
The UK took a decisive step towards legalizing CBD with the reclassification of cannabis-based products for medicinal use in 2018. This change allowed doctors to prescribe cannabis-derived medicinal products, including CBD, to patients with certain conditions.
Additionally, CBD products marketed as food supplements became widely available, provided they contained no more than 0.2% THC and made no medicinal claims. These products are regulated under general food law, and the Novel Food Regulation requires that new CBD products undergo a safety assessment and receive authorization from the Food Standards Agency (FSA) before they can be sold.
Current Status
Today, CBD is legal in the UK as long as it meets specific criteria regarding THC content and product labeling. The market for CBD products continues to grow, with increasing consumer demand and ongoing research into its potential benefits.
Conclusion
Both the United States and the UK have experienced significant shifts in their approach to CBD over the past decade. Legislative changes, growing public awareness, and recognition of CBD’s therapeutic potential have driven the legalization process in both countries. While the regulatory landscapes continue to evolve, the legal status of CBD in the US and UK reflects a broader trend towards accepting and integrating this versatile compound into mainstream health and wellness practices.
